Literature DB >> 2143272

Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of delta 4 desaturation?

M Martínez1.   

Abstract

In confirmation of previous findings, patients with Zellweger's syndrome had extremely low levels of docosahexaenoic acid (22:6 omega 3) in the brain, liver, and kidneys. The other product of delta 4 desaturation, 22:5 omega 6, was also very significantly decreased, as were the ratios 22:6 omega 3/22:5 omega 3 and 22:5 omega 6/22:4 omega 6, especially in the brain and liver of the Zellweger patients. The infant with pseudo-Zellweger's syndrome also had very low levels of 22:6 omega 3 and of the ratio 22:6 omega 3/22:5 omega 3 in all tissues, especially in the brain, where the index 22:5 omega 6/22:4 omega 6 was also very significantly reduced. The ratio 22:6 omega 3/22:4 omega 6 was markedly decreased in all tissues, in Zellweger's as well as in pseudo-Zellweger's syndrome. The findings reported here strongly reinforce the hypothesis of a new enzymatic defect in peroxisomal disorders involving the desaturation of long polyunsaturated fatty acids, especially of the omega 3 family.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143272     DOI: 10.1212/wnl.40.8.1292

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

Review 1.  Peroxisomal disorders: clinical, biochemical, and molecular aspects.

Authors:  R J Wanders
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid.

Authors:  Hee-Yong Kim; Mohammed Akbar; Yang-Suk Kim
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-03-05       Impact factor: 4.006

3.  Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis.

Authors:  M Martinez
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

4.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival.

Authors:  Mohammed Akbar; Frances Calderon; Zhiming Wen; Hee-Yong Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

5.  Plasma and red blood cell fatty acids in peroxisomal disorders.

Authors:  A B Moser; D S Jones; G V Raymond; H W Moser
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

6.  Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease.

Authors:  Giuseppe Astarita; Kwang-Mook Jung; Nicole C Berchtold; Vinh Q Nguyen; Daniel L Gillen; Elizabeth Head; Carl W Cotman; Daniele Piomelli
Journal:  PLoS One       Date:  2010-09-08       Impact factor: 3.240

7.  Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study.

Authors:  M Martinez; I Mougan; M Roig; A Ballabriga
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

Review 8.  Biochemical and biological functions of docosahexaenoic acid in the nervous system: modulation by ethanol.

Authors:  Hee-Yong Kim
Journal:  Chem Phys Lipids       Date:  2008-03-02       Impact factor: 3.329

9.  Abnormal lipid and fatty acid compositions of kidneys from mice with polycystic kidney disease.

Authors:  H M Aukema; T Yamaguchi; H Takahashi; B Celi; B J Holub
Journal:  Lipids       Date:  1992-06       Impact factor: 1.880

10.  Brain lipid concentrations in bipolar disorder.

Authors:  Miki Igarashi; Kaizong Ma; Fei Gao; Hyung-Wook Kim; Deanna Greenstein; Stanley I Rapoport; Jagadeesh S Rao
Journal:  J Psychiatr Res       Date:  2009-09-19       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.